Zelenskyy announces three-year plan for IRIS-T deliveries from Germany
Ukraine and Germany have agreed on a joint plan to supply Kyiv with IRIS-T air defence systems over the next three years.
Source: President Volodymyr Zelenskyy at a briefing following a meeting with German Defence Minister Boris Pistorius, as reported by Interfax-Ukraine
Quote: "We are also grateful for the supply of IRIS-T air defence systems. We now understand the delivery plan – I won't go into all the details. But it's a plan for the next three years, and this is very important support for us regardless."
Details: Zelenskyy stressed that the plan does not imply the war will last that long, but Ukraine requires air defence systems to protect its civilians.
He also noted that Ukraine expects to localise the production of these "very high-quality" German air defence systems.
Background: In May, Ukraine signed agreements with German company Diehl Defence for the production of IRIS-T systems and missiles for Ukrainian use.
Support Ukrainska Pravda on Patreon!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Fabrizio Romano Confirms Florian Wirtz to Liverpool is ‘100% Done'
Liverpool Beat Rivals to Sign Florian Wirtz in Stunning Transfer Coup Liverpool have pulled off a sensational coup in the transfer market, with the signing of Florian Wirtz now '100% done,' according to transfer expert Fabrizio Romano. The Bayer Leverkusen star, widely regarded as one of the brightest attacking midfielders in Europe, has chosen Anfield as his next destination, turning down strong interest from Bayern Munich, Real Madrid and Manchester City. Advertisement Romano confirmed on Tuesday that 'Liverpool verbally agree deal in principle with Bayer Leverkusen for package reaching €150m add-ons included,' adding that the 'player side already agreed two weeks ago with move now imminent' and that 'Wirtz set for medical and contract signing.' The 22-year-old German international, currently on holiday, is expected to complete his move following a medical once the transfer window reopens on 16 June. This delay is due to FIFA Club World Cup regulations. Behind the Deal: Slot's Role and Player Decision This wasn't a transfer engineered overnight. Initial speculation linked Wirtz with Manchester City, especially after he was spotted in England with his parents, who also serve as his representatives. However, those assumptions were quickly flipped on their head. German reports suggested that the Wirtz entourage travelled not to Manchester, but to Merseyside. Advertisement Arne Slot, fresh off a Premier League-winning debut campaign, is believed to have played a pivotal role in securing the player's decision. During his UK visit, Wirtz reportedly held a direct conversation with the Liverpool manager. That meeting appears to have been decisive. The report explains that 'a conversation with the Liverpool boss convinced him to choose a move to Anfield over going to Bayern Munich.' Slot's project, vision and playing style are said to have swayed the attacking midfielder, who has long been touted as the spiritual successor to Mesut Özil in the German national team setup. Photo: IMAGO Mixed Reports but Deal Remains on Track Despite Romano's strong declarations, some sources remain slightly more cautious. A contradictory update came from another senior journalist, who stated there was 'no agreement yet' between the clubs. However, even that statement confirmed that Liverpool and Leverkusen were in the 'final stages' of negotiations. Advertisement Romano doubled down on his position, clarifying that 'I told you two days ago (Tuesday) that the agreement is done. I can confirm that the agreement is done. You can consider Wirtz as a Liverpool player.' The delay in any official confirmation is, according to Romano, entirely due to Wirtz being on holiday. Once he returns, the medical and contract signing are set to follow swiftly. Photo: IMAGO Strategic Timing Ahead of Window Opening With the summer transfer window closed until 16 June, Liverpool and Bayer Leverkusen have time to finalise the structure of the deal, which is said to be complex due to the size of the package involved. Advertisement This breathing room could prove beneficial, as clubs look to iron out technicalities and payment schedules before the move is rubber-stamped. The final valuation, reportedly reaching €150 million including add-ons, represents a record-breaking commitment from Liverpool. But if Wirtz can translate his Bundesliga brilliance to the Premier League, it may well be a bargain in the long run. Our View – Anfield Index Analysis This is seismic. The sort of signing Liverpool fans used to dream about but rarely saw happen unless a star was being sold. To beat Bayern, Real Madrid and Man City to Florian Wirtz speaks volumes not just about Liverpool's pulling power, but also about the Slot effect. Arne Slot hasn't just won the league, he's clearly winning hearts and minds off the pitch too. Advertisement Wirtz is a generational talent. His ability to glide past players, his intelligence between the lines and his fearless creativity are exactly what this team needs to evolve again. While fans are rightly still emotional after the Klopp era, Slot seems to be building something both sustainable and exciting. There's a buzz growing. The thought of Wirtz linking up with Salah, Szoboszlai and Diaz in a fluid front four will have fans counting down the days until pre-season. The fee might be huge, but so was the statement. This is not a rebuild, it's a reload. Credit to Fabrizio Romano for staying consistent on this story. His updates have been the most confident throughout and, once again, he appears to have been proven right.
Forbes
an hour ago
- Forbes
Is LMT Stock A Good Defense Pick Amid Israel-Iran Tensions?
CANADA - 2025/02/08: In this photo illustration, the Lockheed Martin Corporation logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Defense stocks, especially Lockheed Martin (NYSE:LMT), are in the spotlight following the recent assault by Israel on Iran's nuclear initiative. As the primary missile supplier to the U.S. government, Lockheed Martin holds a crucial position. It is noteworthy that 20,000 missiles intended for Ukraine were recently redirected to Israel, as stated by the Ukrainian president. Lockheed Martin has come under scrutiny recently after reports revealed that the Pentagon has drastically cut its request for Air Force F-35s by half. This situation emphasizes potential changes in defense budget allocations and procurement practices. While Lockheed Martin offers an appealing valuation that may attract value investors in the defense industry, it also reveals various operational and financial vulnerabilities that pose inherent risks. Despite these issues, the stock's reasonable pricing in relation to its fundamentals and its proven resilience in market downturns indicate possible upside for those investors with a higher risk tolerance. However, for those aiming for less volatility than single stocks, the Trefis High Quality portfolio serves as an option — having outperformed the S&P 500 and yielding returns above 91% since its launch. In a different context, see – Boeing Stock Faces Fresh Crisis After 787 Dreamliner Crash. Relative to the broader S&P 500, Lockheed Martin's stock is notably priced favorably across various valuation metrics. Its price-to-sales ratio of 1.6 is significantly lower than the S&P 500's 3.0, suggesting that investors are paying much less for every dollar of Lockheed Martin's revenue. This discount also applies to cash flow, as LMT's price-to-free cash flow ratio of 16.6 compares favorably to the S&P 500's 20.5. Likewise, its price-to-earnings (P/E) ratio of 20.3 indicates a significant discount compared to the S&P 500's 26.4. These favorable valuation indicators suggest that the market has possibly already taken into account many of the company's operational obstacles, which could present an opportunity for investors who feel that the current negativity is exaggerated or that improvements are on the horizon. Lockheed Martin's revenue growth reflects a somewhat mixed yet stable trend. In the last three years, the company achieved an average annual revenue growth rate of 3.0%. Although modest, this consistency is notable considering the challenging environment in defense contracting, and it lags behind the S&P 500's average of 5.5%, indicative of the defense industry's mature nature and the cyclicality of government spending. In more recent times, performance has shown signs of progress. Revenue increased by 3.1% over the past twelve months, rising from $70 billion to $72 billion. The latest quarter displayed accelerating momentum, with revenue increasing by 4.5% year-over-year to $18 billion, closely approaching the S&P 500's quarterly growth rate of 4.8%. This recent growth suggests that Lockheed Martin is preserving its competitive stance in key defense markets, despite overall growth remaining moderate. Concerns about profitability represent the most significant risk factor for potential investors. Lockheed Martin's operating margin of 10.3% falls short of the S&P 500 average of 13.2%, reflecting difficulties in converting revenue into operational profits. This weakness is evident throughout the income statement, as the company generated $7.4 billion in operating income from its $72 billion revenue base. Cash flow metrics further emphasize these profitability challenges. The company's operating cash flow margin of 9.4% significantly underperforms the S&P 500's average of 14.9%, leading to $6.7 billion in total operating cash flow over the past four quarters. At the net income level, margins of 7.7% are unfavorably compared to the S&P 500's 11.6%, resulting in net income of $5.5 billion. These margin pressures likely arise from the competitive nature of defense contracting, possible cost overruns on complex programs, and the difficulties associated with managing extensive, multi-year projects that feature fixed-price components. Lockheed Martin's balance sheet offers a mixed view of financial stability. On the positive side, the company maintains a moderate debt-to-equity ratio of 18.2%, which is slightly better than the S&P 500 average of 19.9%. With $20 billion in debt against a market capitalization of $110 billion, the company's leverage appears manageable, providing financial flexibility for its operations and investments. However, the company's liquidity position raises some concerns. Cash and cash equivalents total merely $1.8 billion out of $57 billion in total assets, resulting in a cash-to-assets ratio of only 3.2%. This figure is significantly lower than the S&P 500 average of 13.8%, indicating a limited financial buffer for unexpected challenges or opportunities that require immediate capital allocation. One of Lockheed Martin's key strengths is its ability to withstand market downturns, adding a defensive element to investment portfolios. During the inflation shock of 2022, LMT stock fell by 20.8% from its peak to its trough, better than the S&P 500's decline of 25.4%. The stock showed strong recovery potential, regaining its pre-crisis levels by July 2024 and subsequently reaching new highs of $614.61 in October 2024. Although its defensive characteristics were less apparent during the COVID-19 pandemic in 2020, where it experienced a 37.1% decline compared to the S&P 500's 33.9%, it still managed to recover to pre-crisis levels by March 2022, demonstrating medium-term resilience. During the 2008 Global Financial Crisis, LMT performed slightly better than the overall market, with a decline of 51.4% versus the S&P 500's 56.8%; however, recovery was delayed, reaching pre-crisis levels by July 2013. A thorough analysis of Lockheed Martin indicates a company facing significant operational challenges but balanced by attractive valuation metrics and defensive qualities. While weak profitability and limited cash flow present serious risks that investors must diligently consider, these concerns seem to be incorporated into the stock's current valuation, which trades at substantial discounts across various measures. This analysis favors a contrarian investment approach. Investors contemplating LMT should regard it as a value-oriented investment with inherent volatility, appropriate for portfolios that can accommodate near-term uncertainty. The possibility for long-term appreciation exists as the company addresses its operational hurdles and benefits from ongoing defense spending patterns. We assess Lockheed Martin's Valuationto be $520 per share, indicating over 10% upside potential from the current levels. Investing in a single stock, or a limited number of stocks, always carries considerable risk. Consider Trefis High Quality (HQ) Portfolio which, with a selection of 30 stocks, has consistently outperformed the S&P 500 over the last four years. Why is that? As a collective group, HQ Portfolio stocks have delivered superior returns with reduced risk compared to the benchmark index; resulting in a smoother ride, as evidenced in HQ Portfolio performance metrics.
Yahoo
an hour ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
